AtriCure, Inc. Q1 2007 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2007. AtriCure, Inc. develops, manufactures, and sells surgical devices, primarily the Isolator bipolar ablation system, for the treatment of atrial fibrillation (AF). The company operates in a single segment with sales in the United States and internationally (primarily Europe). As of May 3, 2007, there were 12,304,288 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Revenues | $10,750,770 | $8,636,808 |
| Gross Profit | $8,540,275 | $7,037,067 |
| Gross Margin | 79.4% | 81.5% |
| Net Loss | $(4,302,421) | $(3,089,771) |
| Loss Per Share (Basic/Diluted) | $(0.35) | $(0.26) |
| Cash and Cash Equivalents | $13,186,141 | $23,058,275 |
| Short-term Investments | $2,797,820 | $4,598,032 |
| Total Debt (Current + Long-term) | $989,068 | $1,084,004 |
| Working Capital | $19,525,341 | $23,031,011 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 24.5% to $10.8 million, driven by higher unit sales domestically and internationally. International sales rose to $1.2 million (11.4% of total revenue) from $0.8 million.
- Operating Expenses: Total operating expenses increased 28.9% to $13.4 million. Selling, general, and administrative (SG&A) expenses rose significantly by $2.8 million (37.2%), attributed to increased headcount, marketing expenditures, and a $300,000 accrual for a legal settlement with a former European distributor.
- Profitability: The net loss widened to $4.3 million from $3.1 million due to the increase in operating expenses outpacing revenue growth. Gross margin declined slightly to 79.4% from 81.5% due to a marginal increase in average cost per unit.
- Cash Flow: Net cash used in operating activities improved to $3.0 million from $3.8 million in the prior year. Net cash provided by investing activities turned positive ($1.3 million) due to maturities of available-for-sale securities.
Guidance, Outlook, and Risks
- Outlook: Management anticipates continued increases in absolute R&D and SG&A costs for the remainder of 2007 due to product development and sales expansion, though these are expected to decrease as a percentage of revenue. The company expects international sales to remain relatively constant as a percentage of total sales.
- Regulatory Status: Substantially all revenues are generated through the off-label use of the Isolator system for AF treatment. The company is conducting clinical trials and intends to seek FDA approval for AF treatment as early as 2009. A 510(k) notification for the Cosgrove-Gillinov Left Atrial Appendage Occlusion Clip was filed in Q1 2007.
- Legal Contingencies:
- Class Action: A securities class action lawsuit (Levine v. AtriCure) is pending; the company intends to vigorously defend against it.
- LST Settlement: A tentative settlement was reached in April 2007 with former distributor Life Support Technology (LST). The company agreed to pay approximately $350,000 over four years. A present value of $300,000 was accrued as of March 31, 2007.
- Liquidity: The company holds approximately $16.0 million in cash and short-term investments. Management believes this is sufficient to meet needs for at least the next 12 months.
Investor Verification Checklist
- Off-Label Revenue Dependency: Verify the sustainability of revenue streams given that the primary product is not FDA-approved for its main use case (AF treatment).
- Legal Settlement Impact: Confirm the final terms of the LST settlement and the status of the pending securities class action lawsuit.
- SG&A Efficiency: Monitor the trajectory of SG&A expenses, which rose to 95.6% of revenue, to ensure they decline as a percentage of revenue as projected.
- Regulatory Timeline: Track progress on clinical trials and the 510(k) filing for the new Clip device, as future growth is tied to regulatory approvals.
- Cash Burn Rate: Assess the runway of the $16 million cash position against the current quarterly operating cash burn of approximately $3 million.